<div id="readability-page-1"><div> <div> , /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (&#34;PepGen&#34; or the &#34;Company&#34;) (NASDAQ: PEPG). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether PepGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 4, 2026, PepGen announced in a press release that &#34;[t] he U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1)&#34;, stating that &#34;[t] he partial clinical hold questions raised by FDA relate to previously submitted preclinical pharmacology and toxicology studies.&#34; On this news, PepGen's stock price fell $1.25 per share, or 18.57%, to close at $5.50 per share on March 5, 2026. Then, on March 30, 2026, PepGen issued a press release announcing &#34;clinical data from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1).&#34; Although PepGen characterized the data as &#34;promising,&#34; analysts noted the lack of meaningful improvement in patients' handgrip strength or 10-meter walk/run test. On this news, PepGen's stock price fell $2.46 per share, or 58.16%, to close at $1.77 per share on March 31, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9REMyNjQ4NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIyMTQ0UFJfTkVXU19VU1BSX19fX19EQzI2NDg1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDAyJk5ld3NJdGVtSWQ9REMyNjQ4NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDIyMTQ0UFJfTkVXU19VU1BSX19fX19EQzI2NDg1"/></div> </div></div>

LABU

Pomerantz Law Firm is investigating claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG) regarding potential securities fraud or unlawful business practices by the company and its officers. Following a partial clinical hold by the FDA on a clinical trial, PepGen's stock price fell significantly. The firm encourages affected investors to contact them for more information about joining the class action.

prnewswire

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VG Health

Direxion S&P Biotech Bear 3X

ALPS Medical Breakthrough

iShares US Pharma

PepGen

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

21:44 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG